Fund Sees Globus Medical at Discount After 2.83% Monthly Return and Robotics Hurdles
In its Q4 2025 investor letter, the fund said Globus Medical’s stock returned 2.83% last month while shares traded between $51.79 and $101.40 and closed at $90.46 with a $12.17B market cap. It flagged recent acquisitions, supply chain delays and robotics-segment weakness as drivers of its discounted valuation.
1. Fund Letter Highlights Stock Performance
In its Q4 2025 investor letter, the Small Cap Value Fund noted that Globus Medical delivered a 2.83% return over the past month. The fund emphasized that shares oscillated between $51.79 and $101.40 during the last 52 weeks, closing the period at $90.46 and valuing the company at approximately $12.17 billion.
2. Operational Headwinds Weigh on Valuation
The fund identified recent acquisitions that have yet to fully integrate, ongoing supply chain delays in critical components and underperformance in the robotics segment as key operational headwinds. These factors prompted the fund managers to view the stock as trading below their estimate of intrinsic value.
3. Hedge Fund Interest and Long-Term Outlook
Globus Medical’s presence in 42 hedge fund portfolios at year-end—down from 46 the prior quarter—reflects tempered institutional conviction. Despite near-term challenges, managers highlighted the company’s orthopedic and spinal solutions franchise as underpinning potential long-term capital appreciation.